

**Dimension® clinical chemistry systems
Dimension Vista® System**

N- Acetylcysteine (NAC) and Metamizole Interference with Trinder and Trinder-like reaction Assays

Our records indicate that your facility may have received the following products listed in Tables 1 through 4 that can be processed on Siemens instruments:

Table 1. Dimension Products affected by N-Acetylcysteine (NAC) and Metamizole

Assay	Test Code	Catalog Number	Siemens Material Number (SMN)	Lot Number
Triglycerides	TGL	DF69A	10444906	All
Enzymatic Creatinine	EZCR	DF270B	10444970	All

Table 2. Dimension Products affected by Metamizole only

Assay	Test Code	Catalog Number	Siemens Material Number (SMN)	Lot Number
Automated HDL Cholesterol	AHDL	DF48B	10464332	All
Uric Acid	URCA	DF77	10444967	All

Table 3. Dimension Vista Products affected by N-Acetylcysteine (NAC) and Metamizole

Assay	Test Code	Catalog Number	Siemens Material Number (SMN)	Lot Number
Triglycerides	TRIG	K2069	10445093	All
Enzymatic Creatinine	ECREA	K1270A	10700444	All

Table 4. Dimension Vista Products affected by Metamizole only

Assay	Test Code	Catalog Number	Siemens Material Number (SMN)	Lot Number
High Density Lipoprotein Cholesterol	HDLC	K3048A	10464340	All
Uric Acid	URCA	K1077	10445145	All

Note: Dimension® URCA and Dimension Vista® URCA are not Trinder reaction assays but they do produce peroxide and are susceptible to Metamizole interference.

Reason for Correction

Siemens Healthcare Diagnostics has become aware of N- Acetylcysteine (NAC) and Metamizole (Dipyrone) interference with Trinder and Trinder-like reaction assays. The Trinder reaction is a reaction where hydrogen peroxide is formed and subsequently reacts with a phenol derivative and aminoantipyrine in the presence of peroxidase to form a colored quinone product.

Siemens has confirmed that falsely depressed results may occur on samples drawn from patients receiving N- Acetylcysteine (NAC) or Metamizole as indicated in Tables 1 through 4. NAC is the accepted antidote for acetaminophen toxicity and is justified in patients at significant risk for hepatotoxicity. Metamizole is an anti-inflammatory anti-pyretic drug banned in most countries because of the potential for nephrotoxicity.

The Instructions For Use (IFU) for the Dimension and Dimension Vista assays listed in Tables 1 and 3 (in the Limitations of the Procedure section) will be updated to indicate that: Venipuncture should occur prior to N-Acetylcysteine or Metamizole administration due to the potential for falsely depressed results.

The Instructions For Use (IFU) for the Dimension and Dimension Vista assays listed in Tables 2 and 4 (in the Limitations of the Procedure section) will be updated to indicate that: Venipuncture should occur prior to Metamizole administration due to the potential for falsely depressed results.

Risk to Health

The potential exists for reporting falsely depressed results for the assays listed in Tables 1 through 4 from patients who have been administered NAC or Metamizole. Baseline values before administration of the NAC or Metamizole therapy would not be affected. It is extremely unlikely these assays would be requested during assessment of acetaminophen overdose and NAC treatment.

The potential impact on results due to this issue is limited to only the assays outlined in this communication. Siemens is not recommending a laboratory look back as a result of this issue.

Actions to be Taken by the Customer:

- Please review this letter with your Medical Director.
- Venipuncture should occur before drug administration of NAC or Metamizole as indicated above under Reason for Correction. Baseline assay values before administration of NAC or Metamizole therapy would not be affected.
- Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days.
- If you have received any complaints of illness or adverse events associated with the products listed in Tables 1 through 4, immediately contact your local Siemens Customer Care Center or your local Siemens technical support representative.

N- Acetylcysteine (NAC) and Metamizole Interference with Trinder and Trinder-like reaction Assays on the Dimension and Dimension Vista

Please retain this letter with your laboratory records, and forward this letter to those who may have received this product.

We apologize for the inconvenience this situation may cause. If you have any questions, please contact your Siemens Customer Care Center or your local Siemens technical support representative.

Dimension and Dimension Vista are trademarks of Siemens Healthcare Diagnostics.

N- Acetylcysteine (NAC) and Metamizole Interference with Trinder and Trinder-like reaction Assays on the Dimension and Dimension Vista

FIELD CORRECTION EFFECTIVENESS CHECK

N- Acetylcysteine (NAC) and Metamizole Interference with Trinder and Trinder-like reaction Assays

This response form is to confirm receipt of the enclosed Siemens Healthcare Diagnostics Urgent Field Safety Notice DC16-02.A.OUS dated March 2016 regarding N- Acetylcysteine (NAC) and Metamizole Interference with Trinder and Trinder like reaction Assays on the Dimension and Dimension Vista. Please read the question and indicate the appropriate answer. Fax this completed form to your local Siemens technical support representative.

1. I have read and understood the Urgent Field Safety Notice instructions provided in this letter. Yes No

Name of person completing questionnaire: _____

Title: _____

Institution: _____ Instrument Serial Number: _____

Street: _____

City: _____ State: _____

Phone: _____ Country: _____

Customer Sold To #: _____ Customer Ship To #: _____

Please fax this completed form to your local Siemens technical support representative. If you have any questions, contact your local Siemens technical support representative.